These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27575546)

  • 1. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
    Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
    J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV; Constantine G; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA;
    Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Continuous Transdermal Nitroglycerin for Treating Hot Flashes by Inducing Nitrate Cross-tolerance in Perimenopausal and Postmenopausal Women: A Randomized Clinical Trial.
    Huang AJ; Cummings SR; Ganz P; Schembri M; Raghunathan H; Vittinghoff E; Gibson CJ; Grady D
    JAMA Intern Med; 2023 Aug; 183(8):776-783. PubMed ID: 37273224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.
    Constantine GD; Archer DF; Pollycove R; Jiang W; Altomare C; Pinkerton JV
    Menopause; 2016 Sep; 23(9):957-64. PubMed ID: 27404027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
    Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women.
    Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P;
    Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
    Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
    Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine.
    Simon JA; Chandler J; Gottesdiener K; Lazarus N; He W; Rosenberg E; Wagner JA; Denker AE
    Menopause; 2014 Sep; 21(9):938-44. PubMed ID: 24569618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.